Fujifilm India, a leader in the development and application of imaging and information innovations in healthcare technologies has unveiled its globally proclaimed “Never Stop” series in India. The new film titled, ‘Never Stop Innovating for a Healthier World’ highlights how life-changing technologies can enable people to move beyond their health challenges to pursue all that inspires them.

The campaign articulates the thought on ‘preventive healthcare with a mantra of Innovating for a healthier world.’ While serious diseases may seem to limit an individual’s capabilities and begin to define them, innovative new medical technologies from Fujifilm India can help empower people with the high-functioning imaging solutions and knowledge they need to lead a longer life.

Commenting on the campaign, Haruto Iwata, managing director, Fujifilm India Pvt Ltd, said, “For us, it has been about celebrating the ‘Never Stop’ spirit of people and inspiring them to learn the possibilities that good care can bring. We are aiming at shaping the future of healthcare in India with our leading technologies, equipment’s and solutions. This year, we are showcasing the ways in which we help touch the lives of people through these technologies to lead healthier and better lives.”

Tribhuwan Joshi, Lead, brand communication, PR & CSR Fujifilm India stated, “As part of our global campaign, we are thrilled to strengthen our commitment to ‘Never Stop’ believing, innovating, changing and challenging for a healthier world. We are following a 360-degree approach and the campaign will be promoted across all print and digital mediums like metro stations, airports and hospitals. With this campaign, we aim to offer solutions to the consumers for a safer and healthier tomorrow.”

The digital film, conceptualized and created in collaboration with Cheil India will be premiered across key digital media platforms and leading OTT platform-Zee5.

Jaibeer Ahmad, sr. vice president of Cheil India stated, “The campaign showcases Fujifilm’s unwavering commitment of introducing innovative healthcare products and services to the Indian market. Given the interesting concept of ‘Never Stop’, we thought of creating a film that builds a strong emotional connect with the audience and resonates with the brand”.

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced an agreement to offer its suite of cutting-edge Computed Tomography technology to Vizient members at contracted pricing.

For maximum clinical flexibility, all of United Imaging’s CT scanners (uCT®) are enabled to image a wide variety of patient and exam types, including large patients, patients with metal implants, angiography, and cardiology exams. Advanced applications and advanced post-reconstruction analysis are included with every scanner for comprehensive care. In addition, the Z-Detector architecture enables high resolution and low noise imaging across the entire uCT portfolio, and the software platform is also standard across all systems. United Imaging’s CT scanners also benefit from an Easy-Logic Intelligent Prediction platform combined with intuitive and intelligent workflow to support a sizable daily patient throughput while maintaining high image quality.

Vizient is the largest member-driven performance improvement company in the country with a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and nonacute health care providers and represents more than $100 billion in annual purchasing volume.

“United Imaging is on a mission,” noted Jeffrey M. Bundy, Ph.D., CEO of United Imaging Healthcare Solutions, “one that is well aligned with Vizient’s. Ours is Equal Healthcare for All, and we’re very happy to be able to provide Vizient members with quality and true business value that can help them expand the care they provide.”

United Imaging takes a highly vertically-integrated approach to innovation to help manage both quality and costs and enable the most cutting-edge technology across the entire portfolio. In addition, the company’s bold approach to the U.S. market includes several unique aspects. All-in configurations means that its systems are sold fully loaded with all available features included from the outset, giving customers the flexibility to immediately or in the future provide advanced offerings to patients without additional upgrade costs. Software Upgrades for Life refers to the company’s groundbreaking commitment to provide the latest software upgrades throughout the product lifecycle across its entire installed base at no additional cost to the healthcare provider, helping them provide the highest standards of care. United Imaging also offers a United Performance Guarantee on all full-service agreements, flexible coverage options for in-house biomedical engineer organizations, and customized financing solutions to streamline buying and owning medical equipment.

United Imaging first launched investment in the U.S. market in 2013 with R&D, and since then has established a significant American service, commercial, and artificial intelligence presence. The company opened a regional headquarters in 2018 and a global showroom in Houston in 2020, along with a factory to assemble and ship U.S. products, and a robust training center. It also won a number of awards in 2020, including a top prize in an AI competition held jointly by Facebook and NYU, a gold medal for Most Innovative Company of 2020 from the American Business Awards.

Siemens Healthineers AG announces that the European Commission concluded its review of the planned merger with Varian Medical Systems, Inc. and approved the transaction subject to certain conditions. In accordance with its commitments, the company will continue to keep its imaging and oncology software solutions interoperable with third-party offerings in the future. This concerns the connection of imaging solutions for radiation therapy with third-party oncology software solutions (and vice versa) as well as respiratory motion devices.

“With the EU regulatory approval of the transaction, we have taken another important step forward on the path to combining our two companies. Together with Varian’s strong team, we aim to do everything we can in the future to ensure that people around the world benefit from our efforts in the fight against cancer and to strengthen global healthcare,” said Bernd Montag, CEO of Siemens Healthineers AG.

The closing of the transaction remains subject to receipt of regulatory approvals in other countries and satisfaction of certain other customary closing conditions. Siemens Healthineers still expects to close the merger with Varian in the first half of calendar year 2021.

Varian is a world leader in the field of cancer care, with innovative solutions especially in radiation oncology and related software. With a holistic approach to cancer care, the company is increasingly leveraging technologies such as artificial intelligence, machine learning and data analysis to further improve cancer treatment and expand access to care.

Siemens Healthineers AG announces that the European Commission concluded its review of the planned merger with Varian Medical Systems, Inc. (“Varian”, NYSE: VAR) and approved the transaction subject to certain conditions. In accordance with its commitments, the company will continue to keep its imaging and oncology software solutions interoperable with third-party offerings in the future. This concerns the connection of imaging solutions for radiation therapy with third-party oncology software solutions (and vice versa) as well as respiratory motion devices.

“With the EU regulatory approval of the transaction, we have taken another important step forward on the path to combining our two companies. Together with Varian’s strong team, we aim to do everything we can in the future to ensure that people around the world benefit from our efforts in the fight against cancer and to strengthen global healthcare,” said Bernd Montag, CEO of Siemens Healthineers AG.

The closing of the transaction remains subject to receipt of regulatory approvals in other countries and satisfaction of certain other customary closing conditions. Siemens Healthineers still expects to close the merger with Varian in the first half of calendar year 2021.

Varian is a world leader in the field of cancer care, with innovative solutions especially in radiation oncology and related software. With a holistic approach to cancer care, the company is increasingly leveraging technologies such as artificial intelligence, machine learning and data analysis to further improve cancer treatment and expand access to care.

Medtronic plc, the global leader in medical technology, announced it has received approval from the United States FDA for expanded MRI labeling of its InterStim™ II and InterStim™ Micro sacral neuromodulation (SNM) systems that use SureScan™ MRI leads. The updated MRI Guidelines allow for a wider range of MRI scan parameters and shorter wait time between MRI scans, thereby improving patient access to MRI exams and adding flexibility for MRI providers. It applies to existing and future implants of InterStim systems that use SureScan MRI leads.

“I’m pleased to see medical technology for SNM patients continue to improve,” said Howard Goldman, M.D., professor and vice chairman of Quality and Patient Safety, Glickman Urological and Kidney Institute, Cleveland Clinic. “Optimal MRI labeling is an important enabler of greater access to therapy for patients and alleviates burdens on clinicians’ practices.”

The revised MRI labeling provides more options to patients and physicians than the labeling of the other SNM system on the market:

For MRI scanning facilities with B1+rms technology — the gold standard in MRI scanning technology — the new SureScan MRI lead scanning parameters1 increases B1+rms for 1.5 Tesla scans from 3.0 µT to 4.0 µT, and 3 Tesla scans from 1.3 µT to 2.0µT. B1+rms is the gold standard because it is consistent if a patient has multiple MRI scans across different facilities.2 The competitor’s MRI labeling does not specify parameters for 1.5T scans with B1+rms technology.
The new Medtronic scanning parameters1 increases SAR limits for 1.5 Tesla scans from 0.5 W/kg to 2.0 W/kg; and for 3 Tesla scans from 0.5 W/kg to 1.4 W/kg.
The new labeling also decreases wait time from 60 minutes to 5 minutes for maximum duration scans (30 minutes).

These guideline updates are in addition to the benefit already provided by SureScan MRI technology that impedance checks prior to an MRI scan are not required, providing more efficiency in patient care versus the other SNM system on the market.

“Our updated InterStim SureScan MRI labeling means the best choice in SNM therapy keeps getting better,” said Brooke Story, president, Pelvic Health & Gastric Therapies, which is reported as part of the Restorative Therapies Group at Medtronic. “We have had over 70 FDA approvals for the InterStim portfolio and are committed to continuing to innovate so we can help physicians bring life-enhancing technologies to more patients.”

About InterStim SureScan MRI Technology
SureScan MRI technology is a known and trusted brand by MRI technicians. Built on more than 19 years of full-body MRI research, 10 million simulated patient scans, and more than 1.2 million unique scanning scenarios, Medtronic SureScan MRI systems prioritize patient safety.

About Sacral Neuromodulation
Sacral neuromodulation (SNM) uses a small device to send electrical impulses to the sacral nerves located in the lower back to improve bladder and bowel control. Unlike oral medications that target the muscular component of bladder control, SNM offers control of symptoms through direct modulation of the nerve activity, normalizing the communication between the bladder and the brain.4,5

More than 37 million adults in the United States — almost one in six — suffer from overactive bladder (OAB),6,7 and nearly 20 million Americans — about one in 12 — have bowel incontinence.8,9 Many OAB sufferers limit their lives socially, professionally, and personally.10 However, as many as 45% who suffer from OAB symptoms do not seek treatment and as many as seven in 10 stop using OAB medications within six months due to intolerable side effects or unsatisfying results.

About Medtronic
Medtronic plc , headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Pulse Biosciences, Inc., a novel bioelectric medicine company progressing Nano-Pulse Stimulation technology, announced that the first CellFX® procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company’s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company’s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.

As the first-of-its-kind multi-application platform powered by NPS technology delivering nano-second pulses of electrical energy to non-thermally clear cells while protecting adjacent non-cellular healthy tissue, the CellFX System ushers in a new chapter in dermatology procedures addressing everyday skin lesions.

“I am delighted to be the first aesthetic skin specialist to perform the CellFX procedure in Europe. We see a huge number of patients who are burdened by troublesome skin lesions, such as sebaceous hyperplasia, seborrheic keratoses, and non-genital warts, that can affect them at home, work and socially,” said Dr. Afschin Fatemi, medical director of The S-thetic Group, a network of aesthetic clinics across Germany. “With its non-thermal, cellular mechanism, the CellFX System provides a new, consistent solution to remove a variety of bumps and growths on the face and body that have been historically difficult to treat. I am excited to offer this innovative procedure in our clinics and look forward to the enhanced results and improved patient satisfaction we can expect to achieve.”

The prevalence of SH, SK and common, non-genital warts among patients visiting aesthetic dermatologists today is widespread. Based on a 2020 survey among aesthetic physicians from Germany, Spain and France, an average of 200 patients per month who visit aesthetic dermatology practices present with each lesion type (SH, SK, non-genital warts). Further, patients place greater value on a procedure to treat skin lesions over other popular aesthetic procedures they currently receive and are willing to pay cash to treat multiple lesions in a single visit.1

“We are at the inception of a distinctive new era as we embark on the commercial use of the CellFX System for specific lesion types throughout the European Union. In partnership with leading aesthetic skin specialists across Europe, our ambition is to create a blueprint of best practices that ensures success for the next wave of early adopters,” said Ed Ebbers, Executive Vice President and General Manager, Dermatology, of Pulse Biosciences. “We are honored to work with Dr. Fatemi and we look forward to a promising future in the European market.”

About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse StimulationTM (NPSTM) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.

Israeli Workwear management company Polytex Technologies has witnessed explosive growth in the French market over the past year. Seven new hospitals throughout the country have purchased the company’s fully automated workwear management solution that provides improved protection for health workers, which has become even more critical during the COVID-19 pandemic and leads to significant reduction in the expenses on uniforms.

Over the past twelve months, Polytex has won contracts at major French hospitals in Rouen, Rennes, Pithiviers, Dax, Poissy, Ajaccio and at a large hospital laundry service in the Paris region. This is in addition to the eight hospitals and a pharmaceutical industrial site in various parts of the country, which have already installed Polytex’s workwear and scrubs management solution.

The Polytex solution is fully automated and enables hands-free dispensing and collecting of individual uniforms. The system itself is sealed, keeping garments in a clean environment that is opened only by laundry professionals during collection and restocking. The system is available on a 24/7 basis and often installed at multiple locations enabling staff to receive and return garments in seconds, thereby avoiding unnecessary crowding.

Refilling the machines with fresh clothing is very quick and takes only a couple of minutes.

The units can also be moved to special temporary wards dedicated to infectious diseases like COVID-19. The Polytex automated system is backed by a centralized cloud-based management and monitoring applications for end-to-end tracking.

There are currently over 3,000 Polytex units operating in 20 countries, including the U.S., France, Germany, Spain, and Israel, alongside countries in eastern Europe and Asia.

“In the past year we have nearly doubled our presence in France as the global pandemic has made hygiene an even more critical issue for hospitals,” said Yariv Matzliach, CEO of Polytex. He added that “France is currently one of our largest and strategic markets in Europe and has tremendous growth potential.”

“Polytex’s technology system helped to simplify the distribution of workwear in the hospital and led to a 40% reduction in expenses on uniforms,” said Bernard Loulier, laundry manager at the Centre Hospitalier Regional d’Orleans (CHR), the largest hospital in Orleans. He noted that the actual volume of workwear was reduced as were the amount of storage space needed. The first Polytex station in Orleans was installed at the 5000-staff hospital in 2016. The hospital currently has ten stations installed for dispensing and return of uniforms.

About Polytex Technologies

Polytex Technologies is the de-facto leading brand in automated workwear management solutions. Polytex was established in Israel in 2003 by the Poliner family. The co-founder Tomer Poliner served as the company’s CEO until Polytex received a major investment from the private equity fund Fortissimo Capital in 2019. He now leads the company’s technological and business development activities. Polytex, whose headquarters is located in Caesarea, is now headed by its CEO Yariv Matzliach.

We are pleased to announce the start of a new online training portal for our CLiP® and SWiTCH safety catheters.

The platform offers easily accessible training modules for healthcare professionals who work with our catheters. Here you will find specially designed product training programs for each of our products – CLiP® Neo, CLiP® Winged, CLiP® Ported and SWiTCH.

The first four training modules contain an introduction to the respective product and its appropriate use, specific product features and instructions for handling and care. The modules also provide comprehensive questions and their answers, downloads of product sheets and instructions for use, and a list of recommended literature.

Benefits:

Free 24-hour access to training
Access from different platforms possible
Practical guide to product handling
Individual training certificates (available from Q2 2021)

Access:

Register  to receive your training module at stick-to-safety.com/training .